Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
32.57
Sep 28 • 3:59 PM ET Dollar change+1.37 Percentage change(4.39%)
Aftermarket Close
32.57
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
4.02B
Enterprise Value
2.95B
Income
-
Sales
-
Book/sh
8.48
Cash/sh
9.07
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Jun 10, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.84
P/C
3.59
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
17.91
Current Ratio
17.91
Debt/Eq
0.05
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-0.36
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
37.28%
Insider Trans
91.17%
Inst Own
49.92%
Inst Trans
113.62%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-12.86%
SMA50
-10.10%
SMA200
-3.16%
Trades
Shs Outstand
121.94M
Shs Float
77.48M
52W High
42.49 -23.34%
52W Low
24.51 32.88%
Volatility
10.77% 7.98%
ATR (14)
3.03
RSI (14)
39.91
Beta
-
Rel Volume
1.27
Avg Volume
639.15K
Volume
809,590
Perf Week
-11.81%
Perf Month
-17.10%
Perf Quarter
11.58%
Perf Half Y
-
Perf YTD
-2.34%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
31.20
Price
32.57
Change %
4.39%
Date Action Analyst Rating Change Price Target Change
Jul-06-26Initiated Leerink Partners Outperform $40
Jul-06-26Initiated Guggenheim Buy $40
Jul-06-26Initiated Evercore ISI Outperform
Jul-06-26Initiated BofA Securities Buy $45
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Ph.D.Dr. Mathai Mammen M.D.
Executive VPMs. Teresa L. Jurgensen J.D.
Chief Medical OfficerDr. Mohammed Fawzi Benzaghou M.D.
Scientific Co-FounderMr. John McGee Ph.D.
Chief Financial OfficerMr. Thomas Rodolpho Kotarakos
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorJul 20 '26Buy27.28131,4203,584,88726,416,513Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 21 '26Buy29.2565,9231,928,03226,482,436Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 22 '26Buy29.7747,2501,406,63226,529,686Jul 22 04:55 PM
Levy Guy10% OwnerJun 11 '26Buy20.00500,00010,000,0001,027,000Jun 29 10:41 AM
SEBULSKY ALANDirectorJun 15 '26Buy26.499,065240,13530,000Jun 16 06:19 PM
SEBULSKY ALANDirectorJun 12 '26Buy27.678,435233,39320,935Jun 16 06:19 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 11 '26Buy20.0021,188,750423,775,00026,285,093Jun 15 06:57 PM
SEBULSKY ALANDirectorJun 11 '26Buy20.0012,500250,00012,500Jun 15 05:27 PM